Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (6): 491-497.DOI: 10.3969/j.issn.1673-8640.2019.06.003
• Orginal Article • Previous Articles Next Articles
TONG Minghong1, DING Hui1, JIANG Yinting2, SUN Hanxiao1, XUAN Binbin1, SHENG Huiming1
Received:
2018-09-10
Online:
2019-06-30
Published:
2019-07-04
CLC Number:
TONG Minghong, DING Hui, JIANG Yinting, SUN Hanxiao, XUAN Binbin, SHENG Huiming. Role of the determination of statin metabolism-related gene in the treatment of cardiovascular and cerebrovascular diseases[J]. Laboratory Medicine, 2019, 34(6): 491-497.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.06.003
组别 | 例数 | 年龄 (岁) | 性别 | TC(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男性(例) | 女性(例) | ||||||||||||
心脑血管疾病组 | 141 | 70±12 | 89 | 52 | 4.54±1.23 | 2.70±2.01* | 2.90±1.04 | ||||||
脑梗死组 | 69 | 69±12 | 44 | 25 | 4.38±0.93 | 2.31±1.33* | 2.63±0.81 | ||||||
冠心病组 | 72 | 70±12 | 45 | 27 | 4.71±1.44 | 3.07±2.44* | 3.12±1.69* | ||||||
正常对照组 | 70 | 64±15 | 44 | 26 | 4.48±0.92 | 1.47±0.84 | 2.82±0.81 | ||||||
组别 | HDL-C(mmol/L) | apo A(g/L) | apo B(g/L) | apo E(mg/L) | Lp(a)(g/L) | FFA(mmol/L) | |||||||
心脑血管疾病组 | 1.02±0.31* | 1.16±0.19* | 0.91±0.27 | 44.6±18.0 | 1.89(1.02~4.57)* | 0.65±0.38* | |||||||
脑梗死组 | 1.09±0.36* | 1.17±0.19* | 0.89±0.21 | 44.7±13.4 | 1.66(1.01~3.03)* | 0.58±0.27 | |||||||
冠心病组 | 0.94±0.24* | 1.14±0.20* | 0.93±0.31 | 44.6±21.6 | 2.68(1.07~5.88)* | 0.72±0.46* | |||||||
正常对照组 | 1.23±0.31 | 1.24±0.31 | 0.92±0.22 | 45.3±12.3 | 0.89(0.62~1.50) | 0.49±0.40 |
组别 | 例数 | 年龄 (岁) | 性别 | TC(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男性(例) | 女性(例) | ||||||||||||
心脑血管疾病组 | 141 | 70±12 | 89 | 52 | 4.54±1.23 | 2.70±2.01* | 2.90±1.04 | ||||||
脑梗死组 | 69 | 69±12 | 44 | 25 | 4.38±0.93 | 2.31±1.33* | 2.63±0.81 | ||||||
冠心病组 | 72 | 70±12 | 45 | 27 | 4.71±1.44 | 3.07±2.44* | 3.12±1.69* | ||||||
正常对照组 | 70 | 64±15 | 44 | 26 | 4.48±0.92 | 1.47±0.84 | 2.82±0.81 | ||||||
组别 | HDL-C(mmol/L) | apo A(g/L) | apo B(g/L) | apo E(mg/L) | Lp(a)(g/L) | FFA(mmol/L) | |||||||
心脑血管疾病组 | 1.02±0.31* | 1.16±0.19* | 0.91±0.27 | 44.6±18.0 | 1.89(1.02~4.57)* | 0.65±0.38* | |||||||
脑梗死组 | 1.09±0.36* | 1.17±0.19* | 0.89±0.21 | 44.7±13.4 | 1.66(1.01~3.03)* | 0.58±0.27 | |||||||
冠心病组 | 0.94±0.24* | 1.14±0.20* | 0.93±0.31 | 44.6±21.6 | 2.68(1.07~5.88)* | 0.72±0.46* | |||||||
正常对照组 | 1.23±0.31 | 1.24±0.31 | 0.92±0.22 | 45.3±12.3 | 0.89(0.62~1.50) | 0.49±0.40 |
项目 | 例数 | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) |
---|---|---|---|---|---|
治疗前 | 41 | 4.89±1.65 | 2.53(1.83~4.41) | 0.93±0.24 | 3.12±1.38 |
治疗后 | 41 | 3.70±1.11 | 1.13(0.91~1.58) | 1.10±0.22 | 1.95±0.89 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
项目 | apo A(g/L) | apo B(g/L) | apo E(mg/L) | Lp(a)(g/L) | FFA(mmol/L) |
治疗前 | 1.18±0.22 | 0.93±0.36 | 48.5±26.6 | 3.80(0.72~8.89) | 0.73±0.49 |
治疗后 | 1.12±0.14 | 0.74±0.24 | 36.8±16.9 | 2.00(1.00~6.00) | 0.51±0.22 |
P值 | 0.086 | <0.001 | <0.001 | <0.001 | 0.004 |
项目 | 例数 | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) |
---|---|---|---|---|---|
治疗前 | 41 | 4.89±1.65 | 2.53(1.83~4.41) | 0.93±0.24 | 3.12±1.38 |
治疗后 | 41 | 3.70±1.11 | 1.13(0.91~1.58) | 1.10±0.22 | 1.95±0.89 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
项目 | apo A(g/L) | apo B(g/L) | apo E(mg/L) | Lp(a)(g/L) | FFA(mmol/L) |
治疗前 | 1.18±0.22 | 0.93±0.36 | 48.5±26.6 | 3.80(0.72~8.89) | 0.73±0.49 |
治疗后 | 1.12±0.14 | 0.74±0.24 | 36.8±16.9 | 2.00(1.00~6.00) | 0.51±0.22 |
P值 | 0.086 | <0.001 | <0.001 | <0.001 | 0.004 |
项目 | 例数 | TC | TG | HDL-C | LDL-C |
---|---|---|---|---|---|
ABCB1(2677T>G) | 41 | ||||
GG基因型 | 11 | ||||
治疗前 | 4.86±1.51 | 2.53(1.66~6.60) | 1.01±0.28 | 1.30±0.39 | |
治疗后 | 3.68±1.20* | 1.05(0.84~1.31) | 1.05±0.16 | 2.06±1.20* | |
GT基因型 | 20 | ||||
治疗前 | 4.94±1.93 | 3.10(2.18~4.53) | 0.88±0.17 | 3.12±1.59 | |
治疗后 | 3.62±1.20* | 1.16(0.96~1.60) | 1.10±0.21 | 1.92±0.83* | |
TT基因型 | 10 | ||||
治疗前 | 4.82±1.29 | 1.92(1.49~4.54) | 0.94±0.30 | 2.83±1.05 | |
治疗后 | 3.89±0.88 | 1.18(0.89~2.04) | 1.15±0.31 | 1.90±0.65 | |
ABCB1(3435C>T) | 41 | ||||
CC基因型 | 10 | ||||
治疗前 | 5.40±1.71 | 1.90(1.34~2.83) | 0.96±0.23 | 3.08±1.72 | |
治疗后 | 4.12±1.44* | 1.70(1.03~2.19) | 1.07±0.27 | 2.08±0.90* | |
CT基因型 | 24 | ||||
治疗前 | 4.82±1.68 | 1.48(1.11~2.12) | 0.93±0.27 | 3.18±1.40 | |
治疗后 | 3.56±1.07* | 1.04(0.85~1.61) | 1.11±0.22* | 1.92±0.97* | |
TT基因型 | 7 | ||||
治疗前 | 4.39±1.48 | 1.28(1.05~1.99) | 0.87±0.13 | 2.96±0.87 | |
治疗后 | 3.59±0.58 | 1.12(1.04~1.31) | 1.08±0.17* | 1.88±0.64* | |
SLCO1B1*5(T>C) | 41 | ||||
TT基因型 | 33 | ||||
治疗前 | 4.76±1.65 | 1.63(1.14~2.26) | 0.93±0.24 | 3.06±1.30 | |
治疗后 | 3.70±1.11* | 1.15(1.04~1.64) | 1.09±0.22* | 1.96±0.88* | |
CT基因型 | 8 | ||||
治疗前 | 5.40±1.65 | 2.35(1.40~4.99) | 0.90±0.23 | 3.38±1.77 | |
治疗后 | 3.69±1.20* | 1.06(0.87~2.03) | 1.14±0.25* | 1.94±0.98* |
项目 | 例数 | TC | TG | HDL-C | LDL-C |
---|---|---|---|---|---|
ABCB1(2677T>G) | 41 | ||||
GG基因型 | 11 | ||||
治疗前 | 4.86±1.51 | 2.53(1.66~6.60) | 1.01±0.28 | 1.30±0.39 | |
治疗后 | 3.68±1.20* | 1.05(0.84~1.31) | 1.05±0.16 | 2.06±1.20* | |
GT基因型 | 20 | ||||
治疗前 | 4.94±1.93 | 3.10(2.18~4.53) | 0.88±0.17 | 3.12±1.59 | |
治疗后 | 3.62±1.20* | 1.16(0.96~1.60) | 1.10±0.21 | 1.92±0.83* | |
TT基因型 | 10 | ||||
治疗前 | 4.82±1.29 | 1.92(1.49~4.54) | 0.94±0.30 | 2.83±1.05 | |
治疗后 | 3.89±0.88 | 1.18(0.89~2.04) | 1.15±0.31 | 1.90±0.65 | |
ABCB1(3435C>T) | 41 | ||||
CC基因型 | 10 | ||||
治疗前 | 5.40±1.71 | 1.90(1.34~2.83) | 0.96±0.23 | 3.08±1.72 | |
治疗后 | 4.12±1.44* | 1.70(1.03~2.19) | 1.07±0.27 | 2.08±0.90* | |
CT基因型 | 24 | ||||
治疗前 | 4.82±1.68 | 1.48(1.11~2.12) | 0.93±0.27 | 3.18±1.40 | |
治疗后 | 3.56±1.07* | 1.04(0.85~1.61) | 1.11±0.22* | 1.92±0.97* | |
TT基因型 | 7 | ||||
治疗前 | 4.39±1.48 | 1.28(1.05~1.99) | 0.87±0.13 | 2.96±0.87 | |
治疗后 | 3.59±0.58 | 1.12(1.04~1.31) | 1.08±0.17* | 1.88±0.64* | |
SLCO1B1*5(T>C) | 41 | ||||
TT基因型 | 33 | ||||
治疗前 | 4.76±1.65 | 1.63(1.14~2.26) | 0.93±0.24 | 3.06±1.30 | |
治疗后 | 3.70±1.11* | 1.15(1.04~1.64) | 1.09±0.22* | 1.96±0.88* | |
CT基因型 | 8 | ||||
治疗前 | 5.40±1.65 | 2.35(1.40~4.99) | 0.90±0.23 | 3.38±1.77 | |
治疗后 | 3.69±1.20* | 1.06(0.87~2.03) | 1.14±0.25* | 1.94±0.98* |
[1] | MOZAFFARIAN D,BENJAMIN E J,GO A S,et al.Heart disease and stroke statistics-2016 update:a report from the American Heart Association[J]. Circulation,2016,133(4):e38-e360. |
[2] | 《中国心血管病报告2017》概要[J].中国循环杂志,2018,33(1):1-8. |
[3] | 中国心血管病报告2015[J]. 中华医学信息导报,2016,31(12):11. |
[4] | 张静. 从《中国成人血脂异常防治指南》更新看血脂异常的管理[J]. 中华实用诊断与治疗杂志,2017,31(1):1-3. |
[5] | RODRIGUES A C,PERIN P M,PURIM S G,et al.Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response[J]. Int J Mol Sci,2011,12(9):5815-5827. |
[6] | MAHDY ALI K,WONNERTH A,HUBER K,et al.Cardiovascular disease risk reduction by raising HDL cholesterol-current therapies and future opportunities[J]. Br J Pharmacol,2012,167(6):1177-1194. |
[7] | 陈诗婷,孙津津,司冰心,等. 他汀类药物干预飞行人员冠状动脉粥样硬化的疗效观察[J]. 空军医学杂志,2017,33(3):149-152. |
[8] | PRADO Y,SAAVEDRA N,ZAMBRANO T,et al.SLCO1B1 c.388A>G polymorphism is associated with HDL-C levels in response to atorvastatin in Chilean individuals[J]. Int J Mol Sci,2015,16(9):20609-20619. |
[9] | 贺宝霞,石磊,赵树进. 阿托伐他汀的药物基因组学研究进展[J]. 中国临床药理学杂志,2011,27(11):888-891. |
[10] | 梁瑜,孟真. 临床药师个体化用药服务模式探索[J]. 齐鲁医学杂志,2015,30(1):104-106. |
[11] | 袁小龙,高春梅,梁大虎,等. 常见药物转运体基因多态性对药动学影响及研究进展[J]. 中国医院药学杂志,2016,36(13):1144-1148. |
[12] | 张刚,陈磊,李灵敏,等. SLC01B1 T521C基因多态性对他汀类药物药代动力学影响的Meta分析[J]. 第三军医大学学报,2017,39(10):1036-1043. |
[13] | 续茜桥,徐晓宇,石秀锦,等. 药物转运体基因多态性与不同他汀类药物调脂效果及不良反应的相关性[J]. 中国药房,2017,28(32):4596-4600. |
[14] | 汝继玲,何晓静,邱枫,等. ABCB1基因多态性对卡马西平血药浓度的影响[J]. 中国医院药学杂志,2012,32(11):820-824. |
[15] | 田华,张询研,柳芳,等. ABCB1 C3435T多态性与中国人群中他汀类药物疗效关系的系统评价[J]. 中国药学杂志,2017,52(12):1083-1088. |
[16] | 郑林依,王爽,张峰,等. ABCB1基因多态性对心血管药物疗效的影响[J]. 中华临床医师杂志(电子版),2017,11(9):1569-1572. |
[17] | LI Q,HONG J,WU J,et al.The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment:a meta-analysis[J]. J Clin Lipidol,2014,8( 6):618-629. |
[18] | SU J,XU H,YANG J,et al.ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins:a meta-analysis[J]. Lipids Health Dis,2015,14:122. |
[19] | VOORA D,SHAH S H,SPASOJEVIC I,et al.The SLCO1B1*5 genetic variant is associated with statin-induced side effects[J]. J Am Coll Cardiol,2009,54(17):1609-1616. |
[20] | NIEMI M,PASANEN M K,NEUVONEN P J,et al.Organic anion transporting polypeptide 1B1:a genetically polymorphic transporter of major importance for hepatic drug uptake[J]. Pharmacol Rev,2011,63(1):157-181. |
[21] | 张丹,崔刚,张相林. 结构及基因多态性对他汀类药物药动学的影响[J]. 中国药学杂志,2018,53(1):6-9. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||